Skinvisible Web Sign Up for Updates      T 702.433.7154
Skinvisible - Polymer Delivery System

The Ultimate Polymer Delivery System.

Latest News:

July 9, 2024
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations

Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc., through its wholly-owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, proprietary and patent-protected topical and transdermal dermatology and healthcare products, including treatments for obesity and rare skin disorders. Dermatology-focused treatments include topical products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis, along with sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®. Skinvisible's primary objective is to license these preclinical prescription and over-the-counter products into the global topical drug delivery market, which is estimated at USD 124.90 Bn in 2024. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products. Click here to see current licensees.

The Technology: Invisicare® is a patented technology that enhances how drugs are delivered on, in or through the skin. It can control the release of active ingredients, providing a greater and longer release, while at the same time reducing irritation to the skin. It also binds products to the skin for 4 hours and more, resisting wash-off and rub-off. Skinvisible has developed a portfolio of 40+ topical products using Invisicare (prescription, over-the-counter and cosmeceutical) and also works directly with companies to enhance their products, especially ones coming off patent. Invisicare can be tailored to almost any type of molecule and the needs our customers. Learn more at

Intellectual Property: Skinvisible's value lies in its ability to continually generate new IP on its products formulated with Invisicare. Patent approvals are sought in the U.S. and internationally for the products that are developed. Skinvisible has multiple patents granted, including comprehensive patents on Invisicare, the foundation of all of Skinvisible products. Additionally, Skinvisible has been granted three product specific patents in the US for dermal barrier products, sunscreens (achieved 8-hour photostability of avobenzone) and retinoids (stabilization). There are U.S. and international (PCT) patents pending.   Click here to learn more about our patents.

The Opportunity: Pharmaceutical companies pursue new or improved revenue streams along with protecting their own patented products. New product formulations are expensive and time intensive for companies to undertake. Invisicare allows companies to sell a patent-protected product that has been revitalized with new benefits, providing a new story to help combat generic competitors. A prescription product can generate $100+ million per year; many even more - that's why a pharmaceutical company's investment into an Invisicare formulated product is a very viable option.
Skinvisible Spotlight:

July 9, 2024
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations

June 24, 2024
Skinvisible Expands Obesity Patent Application for Transdermal Delivery

May 29, 2024
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

February 14, 2024
Skinvisible Announces Significant Progress In Licensee's Clinical Trials For Invisicare Formulation Targeting Nethertons Syndrome

More News...


Sign up for Skinvisible Inc. Updates:

Click here
to join our mailing list.
Home    |     About us    |    Technology    |    Products    |    Investors    |    Contact Us    |    Disclaimer & Privacy    |     Sign Up for Updates
© 2008 Skinvisible Pharmaceuticals, Inc.     Note: This website is not intended for Canadian residents.